Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a Add-on Strategy for the Treatment of HBeAg-Positive Chronic Hepatitis B.

Trial Profile

Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a Add-on Strategy for the Treatment of HBeAg-Positive Chronic Hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms ARES
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Nov 2012 Interim results for 160 patients at 48 weeks presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 12 Jul 2011 Planned end date changed from May 2013 to Sep 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top